Analyst doubts gold-based ALS therapy from Clene, calling it ineffective

Adam Feuerstein, a senior biotech writer, published a piece in his Biotech Scorecard newsletter questioning a new ALS treatment.

The company Clene is developing CNM-Au8, which it describes as a highly concentrated aqueous suspension of catalytically active gold nanocrystals – essentially gold microdust in water.

Feuerstein argues that the product lacks credible evidence of efficacy and warns that drinking gold is not a cure for ALS, labeling the claim as speculative.

He suggests that investors and clinicians should remain skeptical until rigorous clinical data are presented.